Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva (NYSE: TEVA) announced publication in the New England Journal of Medicine of Phase 3 SPACE trial results showing AJOVY (fremanezumab-vfrm) significantly reduced monthly migraine days and monthly headache days versus placebo in children and adolescents with episodic migraine.
Key results: MMD reduction 2.5 days with AJOVY vs 1.4 days placebo (difference 1.1 days; P=0.02); MHD reduction 2.6 vs 1.5 days (difference 1.1 days; P=0.02); ≥50% MMD responder rate 47.2% vs 27.0% (P=0.002). The 3-month trial enrolled 237 patients. The data supported FDA approval in August 2025 for preventive treatment of episodic migraine in patients aged 6–17 years weighing ≥45 kg. No new safety signals identified.
Teva (NYSE: TEVA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026 at 8:15 AM PT to review its Pivot to Growth strategy, 2025 results and outlook through 2030. Key 2025 outlook: revenues $16.8–$17.0B, operating margin ~26.2%–27.1%, adjusted EBITDA $4.8–$5.0B, diluted EPS $2.55–$2.65, and free cash flow $1.6–$1.9B. Company expects additional contribution from duvakitug milestones (≈$500M revenue, ~$400M EBITDA, ~$500M FCF). Multi-year targets include low-single-digit revenue growth in 2027, operating profit ~30% in 2027, and free cash flow >$3.5B by 2030.
Teva (NYSE: TEVA) and Royalty Pharma (Nasdaq: RPRX) agreed on up to $500 million to accelerate development of Teva’s anti-IL-15 antibody TEV-’408, including $75 million to co-fund a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option for an additional $425 million to support Phase 3 if Phase 2b results warrant. TEV-’408 is in Phase 1b for vitiligo and Phase 2a for celiac disease. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales.
Teva (NYSE: TEVA) announced that Richard Francis, Teva president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
The presentation starts at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). A live webcast will be available on Teva’s investor relations website and an archived recording will be posted within 24 hours and remain accessible for up to 30 days.
Teva (NYSE: TEVA) received a ratings upgrade and outlook revisions on Dec 24, 2025: S&P raised the long-term rating to BB+ (from BB) with a stable outlook, while Moody's affirmed B1a and moved the outlook to positive from stable.
S&P cited adjusted leverage of 4.4x as of Sept 30, 2025 and expects leverage to drop below 4.25x in coming quarters; Moody's expects leverage toward 3.5x within 12–18 months. Both agencies pointed to deleveraging, returning revenue growth, branded-medicine momentum, biosimilar launches, and strong liquidity as drivers supporting higher ratings.
Alvotech (NASDAQ: ALVO) and Teva (NYSE: TEVA) announced a settlement and license with Regeneron that sets a U.S. market entry date for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), in the fourth quarter of 2026, or earlier under specified circumstances, subject to FDA approval.
AVT06 has already received marketing approvals in the United Kingdom, Japan, and the 30 EEA countries. A January 2024 confirmatory study met its primary endpoint, showing high similarity to Eylea® for neovascular AMD.
Teva (NYSE:TEVA) will release its fourth quarter 2025 financial results on Wednesday, January 28, 2026 at 7:00 a.m. ET.
Teva will host a conference call and live webcast the same day at 8:00 a.m. ET. Investors must register in advance to obtain local or toll-free dial-in numbers and a personal PIN. A live webcast will be available at https://ir.tevapharm.com/Events-and-Presentations, and a replay will be posted within 24 hours on the same site.
Teva (NYSE: TEVA) posted its Q4 2025 Aide Memoire on the company's Investors page to help investors ahead of fourth-quarter results.
The Aide Memoire compiles previously disclosed public information, prior results, management commentary and select independent data. Q4 2025 results are scheduled for Wednesday, January 28, 2026 at 7:00 AM ET, followed by a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) submitted a New Drug Application (NDA) to the FDA on December 9, 2025 for olanzapine extended-release injectable suspension (TEV-'749), an investigational once-monthly subcutaneous long-acting injectable (LAI) for adults with schizophrenia.
The NDA is supported by Phase 3 SOLARIS trial data, including Week 56 results that the company says met efficacy and safety endpoints and showed a profile consistent with oral olanzapine. The formulation uses SteadyTeq copolymer technology, proprietary to Medincell. Olanzapine LAI is not approved by any regulatory authority at this time.
Teva (NYSE: TEVA) announced that the European Commission granted marketing authorizations on Nov 25, 2025 for two denosumab biosimilars: PONLIMSI (biosimilar to Prolia) and DEGEVMA (biosimilar to Xgeva).
The approvals follow positive CHMP opinions and allow Teva to launch both products in key European markets in the coming months. Teva frames the authorizations as a milestone for its biosimilars portfolio and part of its Pivot to Growth strategy to broaden patient access to bone‑health biologics across Europe.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
